
MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion
SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide. SciBrunch will receive… Read More


